SRRK

Scholar Rock Holding has seen its share price move sharply over recent years, which naturally raises a question for anyone looking at the stock today.

Scholar Rock has resubmitted its Marketing Authorisation Application to the European Medicines Agency for apitegromab in spinal muscular atrophy, switching to an alternate fill-finish facility that already supported the U.S. FDA approval of ISEMBYLD in…

Scholar Rock (SRRK) is well positioned for a durable, de-risked commercial ramp in the neuromuscular

Scholar Rock Holding Corporation (NASDAQ:SRRK) secured FDA approval on September 11 for ISEMBYLD, apitegromab-mstn, to treat spinal muscular atrophy in adults and children aged two and older currently receiving survival motor neuron 2 (SMN2)-targeted therapy.

Scholar Rock Holding now carries a slightly higher modelled fair value, shifting from US$59.31 to US$62.06. This places it in line with the low to mid US$60s price targets cited in recent research.

Scholar Rock (SRRK) could face some friction during the early commercialization of Isembyld after th

The U.S. Food and Drug Administration on Friday approved ISEMBYLD (apitegromab-mstn) from Scholar Rock for spinal muscular atrophy (SMA) in adults and pediatric patients aged 2 years and older.

On a call on Monday, the company set a list price of $11,659 per vial of Isembyld, or about $310,000 a year for a typical patient.